UBS Group
AMLX icon

UBS Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

UBS Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,900
Closed -$602K – 9421
2023
Q2 		$602K Hold
27,900
– – ﹤0.01% 4669
2023
Q1 		$819K Hold
27,900
– – ﹤0.01% 4279
2022
Q4 		$1.03M Buy
+27,900
New +$990K ﹤0.01% 4043

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

UBS Group's AMLX Position: Q2 2026 in Review

UBS Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 16% in Q2 2026, selling an estimated $811K and leaving 271,881 shares worth $4.88M. The position accounts for ﹤0.01% of the portfolio, ranked #4190.

UBS Group first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $19.1M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • UBS Group held 271,881 shares of Amylyx Pharmaceuticals worth $4.88M as of Q2 2026.
  • UBS Group sold 52,438 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $811K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4190 holding.
  • UBS Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • UBS Group's Amylyx Pharmaceuticals position peaked at $19.1M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.